Sanofi axes cancer combo, early next-gen diabetes drug

Sanofi
Sanofi said it was culling a combination therapy of its approved oncology monoclonal antibody (mAb) Libtayo alongside its phase 3 experimental anti-CD38 mAb isatuximab in “advanced malignancies.” (Sanofi)

If you’ve been paying attention this week, you’ve seen that nearly every Big Pharma has been sweeping out dead R&D projects: Sanofi, posting its third-quarter data early this morning, is no different.

In its financial results, the French Big Pharma said it was culling a combination therapy of its approved oncology monoclonal antibody (mAb) Libtayo alongside its phase 3 experimental anti-CD38 mAb isatuximab in “advanced malignancies.” The combo had been axed in prostate and lung cancer tests.

Libtayo already has the green light for lung cancer, a form of skin cancer and myeloma, while isatuximab, developed with biotech Immunogen, is under FDA review for relapsed/refractory multiple myeloma (MM), with a PDUFA falling in April next year.

Featured Webinar

From Concept to Market: Overcoming the Challenges of Manufacturing and Clinical Trials

In this webinar we will reveal the inner workings of the manufacturing and pharmacy department of a CRO/CDMO, so you understand the different regulatory and operational considerations faced by a clinical research pharmacy.

Learn how CRO/CDMOs successfully address operational and regulatory challenges for pharmaceutical and biotechnology clients; and how this can make the difference between study success or failure.

Sanofi said this was due to "efficacy considerations," but not concerns over safety. According to ClinicalTrials.gov, it is still being tested in relapsed/refractory MM.

It’s also discontinued work on SAR441255, a trigonal GLP1R/GIPR/GCGR that was in a phase 1 for diabetes/obesity.

This mechanism is gaining ground with its rivals, with Lilly last year posting positive midstage data from its GIP/GLP-1 agonist LY3298176, with several others in phase 1 with their GIP/GCGR/GLP-1 agonists, including Novo Nordisk and Hanmi.

Sanofi’s effort was preclinical last year, but, according to its second-quarter report, starting its phase 1 in the summer. Again, it did not say why it had been removed.

In its results today, Sanofi said it was “well on track,” with sales hitting €9.5 billion ($10.6 billion) for the quarter, up around 1% on a reported basis (but down on CER), and R&D spend at €1.36 billion, also down on this time last year.

Suggested Articles

Xevinapant in combination with standard cisplatin-based chemoradiation therapy (CRT) reduces the risk of death in high-risk patients with locally adva

The agency also gave the company’s diagnostic, run on the high-throughput Panther Fusion laboratory platform, a green light for pooled testing.

Smith & Nephew has signed up to acquire Integra LifeSciences’ orthopedics business focused on the growing upper and lower extremity markets.